Table 1.

Definitions of TZB-induced cardiotoxicity at the time of designing the current clinical trial

Author	Year	N	Setting	Definition of cardiotoxicity
Burstein 20	2001	40	Metastatic breast cancer	LVEF< 50% or decrease by 15%
Leyland-Jones 11	2003	32	Metastatic breast cancer	LVEF<40% or decrease by >15%
Romond 3	2005	1159	Adjuvant	LVEF< 55% or decrease by >16%
Burstein 21	2003	54	Metastatic breast cancer	EF<40%
Bengala 13	2006	53	mixed	EF<50%
Tan-Chiu 22	2005	850	Adjuvant	EF decrease by 10% to < 55%
Piccart-Gebhart 10	2005	1677	Adjuvant	EF< 50% or decrease by 10%
Venturini 5	2006	45	Metastatic breast cancer	EF <45% or decrease by 20%
Guarneri 15	2006	173	Metastatic breast cancer	EF < 50% or decrease by 20%